PMID- 35014679
OWN - NLM
STAT- MEDLINE
DCOM- 20220328
LR  - 20220328
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 25
IP  - 3
DP  - 2022 Mar
TI  - Survival‑related DLEU1 is associated with HPV infection status and serves as a 
      biomarker in HPV‑infected cervical cancer.
LID - 77 [pii]
LID - 10.3892/mmr.2022.12593 [doi]
AB  - Human papillomavirus (HPV) is the most common risk factor for the occurrence of 
      cervical cancer (CC). In recent years, the important roles of long non‑coding 
      RNAs (lncRNAs) in CC have emerged, but studies on the relationship between 
      lncRNAs and HPV‑positive (HPV+) CC remain scarce. The present study aimed to 
      investigate whether lncRNA deleted in lymphocytic leukemia 1 (DLEU1) is 
      associated with HPV infection and explore the clinical significance of DLEU1 in 
      HPV+ patients with CC. DLEU1 expression was detected by reverse 
      transcription‑quantitative PCR. The ability of DLEU1 to screen patients with CC 
      from controls and differentiate individuals with different HPV infection status 
      was evaluated by receiver operating characteristic analysis. The association of 
      DLEU1 with the survival prognosis of patients with CC was assessed by 
      Kaplan‑Meier survival analysis and Cox regression analysis. The RNA Interactome 
      Database was used to predict molecules interacting with DLEU1. The results 
      indicated that DLEU1 expression was significantly upregulated in CC tissues and 
      cell lines, particularly in those that were HPV+. In addition, DLEU1 had a high 
      diagnostic value in discriminating patients with CC and differentiating between 
      HPV+ and HPV‑ patients with CC, and had a certain ability to screen HPV+ 
      controls. DLEU1 was correlated with HPV infection in CC patients. Furthermore, 
      DLEU1 was indicated to be associated with survival prognosis in both total 
      patients with CC and HPV+ patients with CC, and independently predict the 
      prognosis of patients with CC. Most of the molecules interacting with DLEU1 were 
      microRNAs. In conclusion, abnormal DLEU1 expression is associated with HPV 
      infection and may serve as a diagnostic and prognostic biomarker for HPV+ 
      patients with CC.
FAU - Dong, Aiping
AU  - Dong A
AD  - Department of Clinical Laboratory, Weifang People's Hospital, Weifang, Shandong 
      261041, P.R. China.
FAU - Xu, Bin
AU  - Xu B
AD  - Department of Clinical Laboratory, Weifang Center for Disease Control and 
      Prevention, Weifang, Shandong 261061, P.R. China.
FAU - Wang, Zhanzhao
AU  - Wang Z
AD  - Department of Clinical Laboratory, Weifang People's Hospital, Weifang, Shandong 
      261041, P.R. China.
FAU - Miao, Xia
AU  - Miao X
AD  - Department of Clinical Laboratory, Weifang People's Hospital, Weifang, Shandong 
      261041, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20220111
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DLEU1 lncRNA, human)
RN  - 0 (RNA, Long Noncoding)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Biomarkers, Tumor
MH  - Cell Line, Tumor
MH  - Databases, Genetic
MH  - Female
MH  - Gene Expression Profiling
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Papillomavirus Infections/*complications/virology
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - RNA, Long Noncoding/*genetics
MH  - ROC Curve
MH  - Uterine Cervical Neoplasms/diagnosis/*etiology/metabolism/mortality
PMC - PMC8778738
OTO - NOTNLM
OT  - cervical cancer
OT  - diagnosis
OT  - human papillomavirus
OT  - lncRNA
OT  - prognosis
COIS- The authors declare that they have no competing interests.
EDAT- 2022/01/12 06:00
MHDA- 2022/03/29 06:00
PMCR- 2022/01/10
CRDT- 2022/01/11 08:48
PHST- 2021/08/25 00:00 [received]
PHST- 2021/11/01 00:00 [accepted]
PHST- 2022/01/11 08:48 [entrez]
PHST- 2022/01/12 06:00 [pubmed]
PHST- 2022/03/29 06:00 [medline]
PHST- 2022/01/10 00:00 [pmc-release]
AID - 77 [pii]
AID - MMR-25-03-12593 [pii]
AID - 10.3892/mmr.2022.12593 [doi]
PST - ppublish
SO  - Mol Med Rep. 2022 Mar;25(3):77. doi: 10.3892/mmr.2022.12593. Epub 2022 Jan 11.